1 / 6

Dr. Adel Al- Mogren

Dr. Adel Al- Mogren. http://faculty.ksu.edu.sa/adel_almogren/default.aspx. Dr. Adel Al- Mogren. B.Sc Clinical Laboratory Sciences from King Saud University, Dept. of Clinical Laboratory Sciences, February 1994.

oleg
Download Presentation

Dr. Adel Al- Mogren

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr. Adel Al-Mogren http://faculty.ksu.edu.sa/adel_almogren/default.aspx

  2. Dr. Adel Al-Mogren B.ScClinical Laboratory Sciences from King Saud University, Dept. of Clinical Laboratory Sciences, February 1994. M.Sc. Molecular and Tumor Immunology from State University of New York at Buffalo, Department of Clinical Laboratory Sciences, September 1999, for thesis entitled “Peptide Mimicry to a tumor associated antigen: Galb1-3 GalNAc through the use of phage display library”. Ph.D. Clinical Immunology and Immunodiagnostics from University of Dundee, Department of Molecular and Cellular Pathology, April 2003, for thesis entitled “Structural and Functional analysis of Different Forms of IgA1 and IgA2 purified from Human Serum or Colostrum”. Examined by Prof. Brian Sutton, King's College London. almogren@ksu.edu.sa

  3. The Discovery The aim. The antibody. The vaccine. Funds and rewards.

  4. King Fahad

  5. the primary breast tumor was extracted by a little mastectomy on the mouse. One group was treated with the (TF-AG) antibody, and left the other group untreated. Different results. Resulting, with (TF-Ag) binding to vascular endothelium, it is jamming a primary metastatic step and providing a survival advantage. http://lujainshatha.wikispaces.com/

  6. Done By: Lujain al-shraim 431202001 Shathaaltahan 431200977

More Related